Correspondence

Gold exacerbates adjuvant arthritis in the rat

Sir, The selection of drugs for clinical testing as 'slow acting' or 'disease modifying' agents in rheumatoid arthritis (RA) would be greatly facilitated if a suitable animal model was available as a screening test. Rat adjuvant arthritis has been tested in this regard and, despite some claims by others, we have in this laboratory consistently failed to detect any inhibition of disease by drugs such as gold and penicillamine.\(^1\) These experiments have, however, involved administration of the drugs for only relatively short periods compared with the 3-6 months necessary to achieve a response in RA patients. For this reason, we have now studied the influence on adjuvant disease of 12 weeks' pretreatment with gold injections. Sprague-Dawley rats, initially weighing approximately 140 g, received twice weekly intramuscular injections of sodium aurothiomalate (Myocrisin) 5 mg or 0·1 mg, or normal saline for 3 months. All were then challenged with an injection of 0·6 mg dead tubercle bacilli in 0·1 ml mineral oil into a hind footpad. The techniques used, including the method of scoring arthritis (by an observer unaware of treatment allocation), were the same as those employed previously.\(^2\) Intramuscular injections were continued during the period of observation.

Within 3 days of starting the intramuscular injections rats in the high-dose group became obviously toxic, lost weight rapidly, and 50% died. However, the remainder of the group gradually recovered despite continuing to receive gold injections, and by 2 weeks these animals were gaining weight at the same rate as those in the other groups. This curious pattern of toxicity and 'tolerance' remains unexplained. We have noted it before.\(^2\)

At the end of the 3 months' pretreatment 7 rats in each group were challenged with adjuvant. At this stage there was no significant difference in weight between the 3 groups, and the mean weight was 464 g (SD 52·26). Fig. 1 shows the mean joint scores (+1 SD). Such older rats are less susceptible to adjuvant disease; hence the relatively low arthritis scores in the animals receiving saline. By contrast, those receiving the higher dose of gold developed significantly more severe arthritis (at day 21: \(p = 0·011\), Mann-Whitney U test). The animals receiving the lower dose of gold (comparable to the doses used in RA patients) developed arthritis of intermediate severity. However, with the small numbers involved the difference between their scores and those of the control group does not reach statistical significance.

The finding that gold injections exacerbate adjuvant arthritis is at first sight unexpected. However, these results confirm consistent past experience in this laboratory (using shorter courses of the drug), and we have no doubt that this is a genuine effect. Unexpected results can sometimes be more informative than an anticipated outcome.

Much discussion about the action of gold has in the past been based on experiments in which the drug has been added to in-vitro systems. It may be that effects observed in the intact animal are more significant. We speculate that this effect of the drug may be a pointer to its mechanism of action in RA. Experiments by Vernon-Roberts and his colleagues' point to a suppression of macrophage function by gold. Gold could exert its influence in both situations by modifying phagocyte activity: in RA by interfering with phagocytosis of immune complexes within the joint and in adjuvant disease by preventing the clearance of disseminated mycobacterial deposits. In the rat it may be possible to test this.

Bone and Joint Research Unit, D. O. HASKARD
London Hospital Medical College, H. L. F. CURREY
25-29 Ashfield Street, London E1 2AD

Fig. 1 Mean joint scores after injection.

References

Rheumatoid arthritis and type 1 diabetes mellitus

Sir, I read with interest the letter from Dr Rudge.1 We had reported a study2 in which we demonstrated an increased prevalence of type 1 diabetes and autoimmune thyroid disease in close relatives of patients with classical or definite rheumatoid arthritis. The rheumatoid patients demonstrated an increased prevalence of organ specific autoantibodies when compared to a control group with degenerative joint disease. We also included several pedigrees demonstrating the close relationship between rheumatoid arthritis and type 1 diabetes within some families. Dr Rudge’s study was carried out at Nottingham along similar lines, but her study did not confirm our findings. It was mentioned by her that both the hospitals in which our study was carried out have an interest in the immunogenetics of these diseases and that this could attract the sort of cases we were interested in. In fact both rheumatology clinics service busy districts and there were very few referrals from outside our catchment areas. I suspect that this alone is not enough to explain the discrepancy.

Our original hypothesis was that the increased prevalence of type 1 diabetes in close relatives of rheumatoid patients could be predicted from the association between both these diseases with HLA DR4. We mentioned in the concluding paragraph of our paper that we would like to study HLA genotypes in families where one sibling had rheumatoid arthritis and another sibling had type 1 diabetes or other autoimmune endocrine disease. Since our paper was published we have studied some of the original families reported and others not included in the study; we have also studied some patients with coexistent type 1 diabetes and rheumatoid arthritis. Although this work is at a preliminary stage there is no clear association between these two diseases and HLA DR4 in the families and individual patients studied.

The pedigrees of families with coexistent rheumatoid arthritis and type 1 diabetes suggest a relationship between these two diseases, and we are confident that a mechanism for the common genetic susceptibility will be identified.

St Bartholomew’s Hospital,
West Smithfield,
London EC1A 7BE

D. J. B. THOMAS

References

Salicylate—NSAID interactions

Sir, We were interested in the paper of Garrett and co-workers concerning interactions between salicylates and other NSAIDs using a rat model of inflammation. The authors found a lack of additive effect or antagonism between salicylates and most of the other NSAIDs tested, although they did not show whether this was likely to represent a pharmacokinetic or pharmacodynamic interaction.

In the previous study in patients with rheumatoid arthritis quoted by Garrett et al., there was no additive effect between
Gold exacerbates adjuvant arthritis in the rat.

D O Haskard and H L Currey

*Ann Rheum Dis* 1984 43: 350-351
doi: 10.1136/ard.43.2.350

Updated information and services can be found at:
http://ard.bmj.com/content/43/2/350.citation

**Email alerting service**

These include:

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/